2010;19:2647-2654. Published online October 6, 2010.
Cancer Epidemiol Biomarkers Prev
Daniele Calistri, Claudia Rengucci, Andrea Casadei Gardini, et al.
Individuals
Positive
−
Immunochemical Fecal Occult Blood Test
Fecal DNA for Noninvasive Diagnosis of Colorectal Cancer in
Updated Version
10.1158/1055-9965.EPI-10-0291
doi:
Access the most recent version of this article at:
Cited Articles
http://cebp.aacrjournals.org/content/19/10/2647.full.html#ref-list-1
This article cites 25 articles, 8 of which you can access for free at:
E-mail alerts
Sign up to receive free email-alerts
related to this article or journal.
Subscriptions
Reprints and
.
pubs@aacr.org
Department at
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Permissions
.
permissions@aacr.org
Department at
Fecal DNA for Noninvasive Diagnosis of Colorectal Cancer in
Immunochemical Fecal Occult Blood Test
–Positive Individuals
Daniele Calistri1, Claudia Rengucci1, Andrea Casadei Gardini1, Giovanni Luca Frassineti1, Emanuela Scarpi1, Wainer Zoli1, Fabio Falcini2, Rosella Silvestrini1, and Dino Amadori1
Abstract
Background:We aimed to define the potential of the fecal DNA assay as an alternative or in addition to the currently used immunochemical fecal occult blood test (iFOBT) for the early diagnosis of colorectal cancer.
Methods:A total of 560 individuals aged 50 to 69 years with a positive iFOBT were recruited from an Italian FOBT regional screening program. Twenty-six were diagnosed with adenocarcinoma, 264 with high-risk adenoma, and 54 with low-risk adenoma, whereas 216 subjects did not have premalignant or malignant lesions. Fecal DNA integrity was analyzed blindly by the fluorescence long DNA (FL-DNA) test. Results:iFOBT and FL-DNA were largely independent variables (rs = 0.036, P = 0.42), with values ranging from 101 to 5,826 ng/mL and from 0 to 515 ng, respectively. Median values of both variables were signifi-cantly higher in cancer patients than in patients with noncancerous lesions or in healthy individuals. More-over, iFOBT and FL-DNA values were individually associated with a number of pathologic parameters. Sequential use of the diagnostic iFOBT and FL-DNA methods showed that fecal DNA provided more accu-rate diagnostic information and was able to identify subgroups at different risk of cancer in iFOBT-positive individuals.
Conclusions:A combined approach based on FL-DNA and iFOBT evaluation could help to better identify colorectal cancers and to determine a patient's risk of harboring a preneoplastic or neoplastic lesion. Further evaluation in a screening setting is needed to confirm this hypothesis.
Impact:Fecal DNA could be a useful tool to better predict cancer risk in FOBT-positive individuals.Cancer Epidemiol Biomarkers Prev; 19(10); 2647–54. ©2010 AACR.
Introduction
The clinical outcome and quality of life of colorectal cancer patients have markedly improved over the last 20 years. This achievement is due partly to progress made in medical and surgical treatments, and to advances in the early noninvasive diagnosis of small tumors and preneoplastic lesions at high risk of malig-nant transformation. Cancers of the colon, like those of the breast and uterine cervix, are good targets for early diagnosis because they are often preceded by preneoplas-tic lesions that typically have a long natural history. In fact, the overall 5-year survival for colorectal cancer patients is around 64%, rising to almost 90% if tumors are diagnosed early (1, 2).
The fecal occult blood test (FOBT) is the most com-mon diagnostic procedure for the early detection of colorectal cancer, and although it reduces mortality by 13% to 33% depending on the test interval and the specific methodologies used (3-6), it does present important limitations, i.e., high number of colorectal cancers missed, suboptimal sensitivity in detecting pre-cancerous lesions such as polyps and adenomas, and difficulty in distinguishing between low- and high-risk lesions in the latter subgroup. These problems have still not been resolved, despite notable improvements in FOBT sensitivity and specificity and new screening strategies (6-8).
The analysis of DNA alterations present in tumor cells exfoliated into feces could represent an interesting alter-native to or support for noninvasive approaches current-ly used. Although the majority of studies published on this subject offer somewhat preliminary data, the biolog-ical rationale for such a diagnostic procedure seems very promising (9-12). Indeed, although bleeding is an inter-mittent and largely unspecific event, cellular exfoliation is a continuous process, which could thus improve test sensitivity. Normal colon epithelium renews itself each day, and this process is coupled with a continuous exfo-liation of cells in the intestinal lumen (13, 14). Moreover, a
Authors' Affiliations:1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola and2Cancer Prevention Unit, Morgagni-Pierantoni Hospital, Forlì, Italy
Corresponding Author: Daniele Calistri, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Via Piero Maroncelli 40, 47014 Meldola (FC), Italy. Phone: 39-0543-739229; Fax: 39-0543-739221. E-mail: d.calistri@irst. emr.it
doi: 10.1158/1055-9965.EPI-10-0291
©2010 American Association for Cancer Research.
number of studies have shown that cellular exfoliation is more pronounced in colorectal cancer patients than in healthy individuals. Although colon cancers typically ac-count for <1% of the total colon surface area, tumor cell DNA actually makes up between 14% and 24% of the total DNA recovered in feces (15, 16). The first evidence that fe-cal DNA quantity and quality might be good indicators of the presence of neoplastic cells emerged more than 10 years ago (15). Since then studies have shown that the simple analysis of fecal DNA fragments greater than 200 bp is capable of identifying patients with tumors or precancerous lesions (16-18). The discrepancy between cancer patients and healthy individuals could reflect the different degradation pathways followed by cells once they pass into the lumen. Normal cells not yet undergoing apoptosis immediately activate this pathway, initiating DNA cleavage and producing small molecules of around 150 to 200 bp in length (17). Conversely, neoplastic cells are able to survive much longer due to the inhibition of apo-ptotic and cell death processes. Once in the lumen, tumor cells are almost certainly destroyed by bile salts, leading to the break-up of cell membranes. In this instance, however, DNA is less damaged and in many cases is composed of fragments of more than 150 to 200 bp in length.
In our laboratory, the method currently used to analyze fecal DNA integrity was modified to ensure a quantitative evaluation [fluorescence long DNA (FL-DNA)], obtaining specificity and sensitivity of up to 80% (19). After complet-ing pilot and confirmatory case-control studies (19, 20), our next step, in accordance with international guidelines (21, 22), was to validate the marker in a large series of candidates for colorectal screening before being able to transfer the application to clinical practice.
As the FOBT test has been shown to produce a high num-ber of false-positive results, we also aimed to assess whether the FL-DNA test could improve specificity in a large series of consecutively enrolled immunochemical iFOBT (iFOBT)-positive individuals by reducing false-(iFOBT)-positive results.
Materials and Methods
Case series
Study subjects were recruited from a colorectal cancer population screening program run by the Oncology Pre-vention Unit of Morgagni-Pierantoni Hospital (Forlì, Italy). The screening program, activated in March 2005, invites men and women aged between 50 and 69 years to undergo a simple test every two years for the detection of fecal occult blood. People testing positive are invited to undergo colonoscopy to verify the nature of the occult blood.
A total of 560 FOBT-positive individuals were enrolled in the study, and all were submitted to endoscopic exami-nation to confirm diagnosis; 26 were diagnosed with ade-nocarcinomas, 264 with high-risk adenomas, and 54 with low-risk adenomas. More than one third of the series (n = 216) did not show any malignant or premalignant lesion at endoscopic examination. The type of lesion was histologically confirmed, and, in cancer patients, pathologic
stage was defined according to Dukes' classification. Preneoplastic lesions were classified as low- or high-risk according to National Comprehensive Cancer Network guidelines (23). Specifically, patients were considered at high-risk when they had high-risk dysplasia, >3 adenoma-tous villous or tubulovillous polyps, at least one of which with a diameter of≥1 cm, or an in situ carcinoma, whereas those who presented with <3 tubular polyps with a diam-eter <1 cm were considered at low-risk. Lesions were divid-ed into subgroups according to localization: proximal colon, from cecum to transverse colon; distal colon, from descending colon to sigmoid colon; rectum; and mixed, lesions affecting both proximal and distal colon.
The study protocol was reviewed and approved by the local ethics committee. Written informed consent was ob-tained from all individuals agreeing to take part in the study. iFOBT test
The fecal occult blood test used is based on an immuno-logical analysis (Alfa Wassermann) and was done only once, in accordance with Regional Screening Program guidelines. Individuals were provided with instructions for collecting the fecal material at home, and samples had to be brought to the analysis laboratory within 24 hours.
In accordance with regional guidelines, test positivity was defined as a hemoglobin value≥100 ng/mL. Hemo-globin values are determined using an immunochemical technique (OC Micro Sensor). Polystyrene latex particles coated with human hemoglobin are mixed with the fecal sample. Antibodies react with the latex agglutination an-tigen, resulting in a change in the turbidity of the sample. As there is a direct proportionality between antigen con-centration and increased turbidity, the concon-centration of hemoglobin can be photometrically calculated. There is no pretest dietary preparation.
FL-DNA test
The stool samples were the same as those used for the hemoglobin analysis. Specifically, iFOBT-positive feces (about 10 mg) remaining on the dipstick after occult blood test analysis were used for the FL-DNA test. Samples were immediately processed for DNA extraction or stored at -20°C for a maximum of 2 months on the basis of results from preliminary experiments on DNA stability.
DNA purification. After a preliminary study in which we assessed the reliability of the analysis carried out on smaller quantities (5-10 mg) of stool compared with the 200 mg previously used by our group (19, 20), stool sam-ples were thawed at room temperature and homogenized with 10 mL of TE-9 buffer [0.5 mol/L Tris-HCl (pH 9), 20 mmol/L EDTA, and 10 mmol/L NaCl]. After centrifuga-tion at 5,000 g for 15 minutes to remove all particulate matter, the supernatant was transferred to a tube containing 150μL of 7.5 mol/L ammonium acetate (M-Medical) and 930μL of 100% ethanol (Carlo Erba). DNA was recovered by centrifugation at 5,000 g for 15 minutes at room temper-ature, resuspended in 1.6 mL of ASL buffer, and purified by QIAamp DNA Stool Kit (Qiagen).
Calistri et al.
Cancer Epidemiol Biomarkers Prev; 19(10) October 2010 Cancer Epidemiology, Biomarkers & Prevention 2648
DNA analysis. The fluorescence intensity of each sample-specific PCR product was determined with fluorescent-labeled primers, as described previously (20). Briefly, exons 5 to 8 of p53 and four fragments of Adenomatous polyposis coli (APC) exon 15 were amplified in a final volume of 25μL containing 2 μL of stool DNA, 0.4μmol/L of each primer, 200 μmol/L of deoxynucleo-tides (Takara Bio Inc), 1× reaction buffer with 3.5 mmol/L
MgCl2(Qiagen), and 1 U of Taq polymerase (Qiagen). The
reaction mixture was subjected to 32 cycles: 60 seconds at 94°C, 60 seconds at 60°C for p53 exons, and 58°C for APC fragments, followed by incubation at 72°C for 60 seconds. Primers used were end-labeled with fluorochromes pro-vided by Applied Biosystems.
The p53 exons were amplified simultaneously in a single reaction mixture, whereas the four APC fragments were
Table 1. FOBT and FL-DNA values in healthy individuals and in patients with different types of lesions
n iFOBT median value (range), ng/mL FL-DNA median value (range), ng
No lesions 216 222 (101-4,156) 13 (0-140)
Low-risk adenomas 54 246 (102-2,344) 12 (0-89)
High-risk adenomas 264 327 (101-5,826) 12 (0-153)
Tumors 26 1,511 (201-3,811) 38 (4-515)
NOTE: FOBT: tumors versus others,P < 0.0001. FL-DNA: tumors versus others P < 0.0001.
Table 2. FOBT and FL-DNA values in relation to clinical and pathologic characteristics in adenoma
patients
Variables Cases (n = 318)
iFOBT (ng/mL) FL-DNA (ng) Median (range) P Median (range) P Age (years) 50-59 96 295 (101-5,826) 9 (0-153) 60-69 222 327 (101-4,986) 0.73 13 (0-148) 0.04 Gender Male 213 364 (101-5,826) 11 (0-153) Female 105 281 (101-4,986) 0.06 13 (0-148) 0.50 Dysplasia Moderate-Low 245 315 (101-5,826) 12 (0-153) Severe 58 327 (101-3,398) 11 (0-148) Not specified 15 134 (108-2,325) 0.09 22 (0-127) 0.43 Microscopic appearance Tubular 135 288 (102-4,986) 12 (0-153) Villous 169 356 (101-5,826) 12 (0-148) Not specified 14 375 (102-1,119) 0.19 10 (0-62) 0.99 Macroscopic appearance Pendunculated 208 355 (101-5,826) 10 (0-148) Sessile 110 256 (101-3,398) 0.003 14 (0-153) 0.04 Lesion dimension 0-1.9 cm 151 251 (101-4,378) 11 (0-112) ≥2 cm 166 426 (101-5,826) 0.0001 13 (0-153) 0.72 Number of lesions Single 122 315 (101-4,378) 10 (0-148) Multiple 196 303 (101-5,826) 0.68 13 (0-153) 0.11 Lesion localization Proximal colon 32 223 (101-1,954) 10 (0-50) Distal colon 153 333 (101-5,826) 10 (0-153) Rectum 39 327 (101-4,986) 9 (0-89) Mixed 94 290 (101-3,723) 0.16 17 (0-137) 0.0
amplified in two different mixes (mix 1, fragments 3 and 4; mix 2, fragments 1 and 2). Electrophoresis was carried out using a 3100 Avant Genetic Analyzer (Applied Biosystems) equipped with GeneScan Analysis 3.7. The final FL-DNA value was obtained by analyzing the fluorescence intensity of each sample-specific PCR product against a reference standard curve (1, 2, 5, 10, and 20 ng) of genomic DNA, and expressed as nanograms. Three different standard curves were prepared: p53 exons 5 to 8, APC fragments 1 to 2, and APC fragments 3 to 4. All samples were run in duplicate and only intersample variations of <15% were ac-cepted. In all other cases (15% of the series), the determina-tion was done on a third sample, with only <10% variadetermina-tions accepted for the entire series. Samples showed no variations >10% at this third evaluation. All samples were amplified with a reaction mix containing 25 attograms of a plasmid with a control sequence to verify the presence of Taq inhibitors.
Statistical analysis
The relationship between FL-DNA and iFOBT values and clinical-histopathologic characteristics was analyzed using nonparametric ranking statistics (median test), whereas Spearman's coefficient (rs) was used to investigate the relationship between FL-DNA and FOBT. To estimate
post-test probability, i.e., the probability of disease in a subject after the diagnostic test results are known, we first estimated the pretest probability and determined the likeli-hood ratio. The pre-test probability is the chance of having the disease prior to testing and this is usually related to the disease prevalence. The likelihood ratio is the ratio of the probability of the specific test result in people who do have the disease to the probability in people who do not. The results were divided into three classes according to different cutoff values (0-9, 10-29, and≥30 ng) to determine the FL-DNA likelihood ratio, which was calculated by dividing the percentage of patients with colorectal cancer by the percentage without disease in each class. Finally, post-test probability was calculated by multiplying the likelihood ratio of the diagnostic test result by the pre-test probability. All P values were two-sided and values≤0.05 were consid-ered statistically significant. All analyses were carried out with SAS Statistical package version 9.1 (SAS Institute Inc.).
Results
iFOBT and FL-DNA values in relation to clinical-pathologic characteristics
In the overall series, iFOBT hemoglobin values ranged from 101 to 5,826 ng/mL, with a median value
Table 3. FOBT and FL-DNA values in relation to clinical and pathologic characteristics in cancer patients
Variables Cases (n = 26)
iFOBT (ng/mL) FL-DNA (ng) Median (range) P Median (range) P Age (years) 50-59 2 1,916 (1,633-2,200) 63 (24-101) 60-69 24 1,314 (201-3,811) 0.48 38 (4-515) 0.74 Gender Males 16 1,314 (201-3,707) 27 (4-236) Females 10 1,691 (434-3,811) 0.94 75 (10-515) 0.07 Dukes' classification A 11 471 (201-3,707) 41 (4-347) B 12 2,027 (204-3,811) 35 (10-236) C 2 497 (434-559) 271 (26-515) D 1 1,237 0.15 34 0.85 Staging Stage I 17 872 (201-3811) 41 (4-347) Stage II 6 2,213 (1390-2929) 36 (12-236) Stage III 2 497 (434-559) 271 (26-515) Stage IV 1 1,237 0.09 34 0.80 Tumor-node-metastasis classification T1 11 1,633 (201-3,707) 41 (4-347) T2 8 703 (204-3,811) 32 (10-515) T3 6 2,081 (1,237-2,929) 40 (24-236) T4 1 559 0.36 26 0.83 Lesion localization Proximal colon 5 467 (434-2,929) 45 (16-515) Distal colon 16 1,569 (204-3,811) 25 (4-347) Rectum 5 1,633 (201-1,962) 0.83 96 (42-123) 0.02 Calistri et al.
Cancer Epidemiol Biomarkers Prev; 19(10) October 2010 Cancer Epidemiology, Biomarkers & Prevention 2650
of 289 ng/mL. The lowest levels were observed in indi-viduals with no lesions (median value, 222 ng/mL) and in low-risk adenoma patients (246 ng/mL). A some-what higher but not statistically different median value (327 ng/mL) was recorded in patients with high-risk adenomas. Considered together, the median iFOBT value for these three subgroups was about five times lower and statistically different (P = 0.0001) from that observed for cancer patients (1,511 ng/mL; Table 1).
Similar results were observed for FL-DNA values. In particular, median values were comparable for indivi-duals with no lesions (13 ng) or with low- and high-risk adenomas (12 ng), and were >3-fold higher (38 ng; P < 0.0001) in cancer patients (Table 1). Correlation coefficient analysis carried out on the overall series showed that FL-DNA and FOBT values were largely independent vari-ables (rs = 0.036, P = 0.42). The relationship between iFOBT and FL-DNA values within the different clinical and pathologic subgroups was analyzed separately in adenoma and cancer patients. In adenoma patients, FOBT median values were significantly higher in those with pedunculated rather than sessile adenomas (P = 0.003), as well as in patients with larger (>2 cm) rather than smaller lesions (P = 0.0001; Table 2). The FL-DNA median value was higher in older than in younger
patients with adenoma (P = 0.04). Moreover, in contrast to what was observed for iFOBT, the DNA median value was higher in patients with sessile rather than pedunculated lesions (P = 0.04) and in patients with mixed lesion localization compared with those with ad-enomas in the proximal or distal colon or rectum (P = 0.02; Table 2).
In cancer patients, FOBT values were not related to ei-ther clinical (age, gender) or pathologic (stage, tumor site) characteristics, whereas median FL-DNA levels were about 3-fold higher in females than in males (P = 0.07), and significantly (P = 0.02) and progressively higher in patients with tumors sited in the proximal or distal colon or rectum (Table 3).
iFOBT and FL-DNA combination analysis
Finally, we evaluated whether the combination of iFOBT and FL-DNA could improve our ability to predict the presence of a tumor. Taking into account the diagnos-tic relevance of fecal hemoglobin and DNA as indepen-dent variables, we tested whether and to what extent the FL-DNA assay could improve iFOBT diagnostic accura-cy. The nomogram provides a graphical tool for estimat-ing how much the result of a test changes the probability that a patient has the disease (Fig. 1). A line is drawn
connecting the pretest probability and the point on the middle vertical line corresponding to the likelihood ratio for the test result, represented by a range of test results (boxes). This line is extended to intersect with the right-hand vertical line, which gives the post-test probability. This point is the new estimate of probability that the patient has the disease. These data are also summarized in Table 4. In this first stage of the study the analysis was limited to iFOBT-positive individuals. We started from three main subgroups at low (101-200 ng/mL), intermediate (>200-1,000 ng/mL), and high (>1,000 ng/mL) iFOBT levels and used different retro-spectively defined DNA cutoffs. In the low-iFOBT sub-group, the probability of there being a tumor was 0, and FL-DNA did not add any useful information. Converse-ly, in the two classes at intermediate and high FOBT levels, the probability of cancer was modulated by FL-DNA values. Specifically, in the intermediate iFOBT subgroup with its 4.6% overall probability of having cancer, breakdown analysis as a function of FL-DNA highlighted a subgroup with <9 ng of FL-DNA that had a 0.9% probability of having cancer and, on the other hand, a subgroup with ≥30 ng of DNA with a 13% probability of having neoplastic disease. A similar modulation was observed for the high FOBT level subgroup in which the probability of having cancer in-creased up to 30% as FL-DNA levels inin-creased, with a maximum cancer prevalence of 32%. Finally, it is worth mentioning that, of the 15 individuals with fecal DNA levels >100 ng, 5 had cancer and 5 high-risk adenomas, independently of FOBT values, which ranged from 109 to 2,282 ng/mL.
Discussion
There is no standard screening program for colorectal cancer, each country implementing its own, with conse-quent limitations and advantages (24). However, the over-all benefits of colorectal cancer screening in reducing cancer mortality are widely acknowledged. This important result is ascribable to early cancer detection, which
im-proves prognosis, but also to the removal of nonmalignant precursor lesions, which prevents cancer development. Although the FOBT is the standard noninvasive approach for early colorectal cancer diagnosis, it fails to detect a large number of cancers (6, 25). Moreover, because FOBT is based on the analysis of occult bleed-ing, which is not necessarily associated with cancer, numerous false-positive results ensue, leading to unnec-essary invasive endoscopic examinations and further psychological stress for patients.
A new and promising strategy for the noninvasive diagnosis of colorectal cancer is based on the analysis of DNA from exfoliated cells excreted in stool (9, 10, 12). Results comparing stool genomic DNA analysis with the nonrehydrated Hemoccult II FOBT test in a large prospective screening cohort showed higher sensitivity in detecting all cancers, and comparable specificity (26).
In preliminary case-control studies, we showed the po-tential of fecal DNA levels in detecting colorectal cancer (19, 20). In the present study we compared the diagnostic accuracy of fecal DNA and fecal occult blood in a large series of iFOBT-positive individuals enrolled in a screen-ing program and for whom histologic diagnosis through endoscopic examination was available.
Furthermore, we modified our previously used meth-odology (19, 20) to carry out iFOBT and FL-DNA analysis on the same small sample of stool.
First, our results confirmed that iFOBT and fecal DNA levels were significantly higher in cancer patients than in patients with low- or high-risk adenomas and in healthy individuals. Second, in patients with neoplastic and pre-neoplastic lesions, analysis on the overall series showed that fecal DNA and FOBT values were variously related to the different lesion and patient characteristics and were largely independent variables, as highlighted by the low correlation coefficient. Specifically, in adenoma patients, iFOBT values were significantly and directly related to the dimension and macroscopic pedunculated appearance of the adenoma, suggesting that structural characteristics cause a more extensive extrusion of the lesion surface into the lumen and probably a higher risk of abrasion with
Table 4. Cancer risk and prevalence as a function of FOBT and FL-DNA evaluations
iFOBT classes (ng/mL) Cases Risk FL-DNA classes (ng) Cases Risk Prevalence iFOBT (%) iFOBT + FL-DNA (%) iFOBT + FL-DNA (%)
101-200 0-9 88 0 0 201 0 10-30 72 0 0 ≥30 41 0 0 201-1,000 0-9 102 0.9 1 239 4.6 10-30 92 4.1 4 ≥30 45 13.0 13 >1,000 0-9 40 2.5 2 120 12.5 10-30 52 11.3 10 ≥30 28 30.8 32 Calistri et al.
Cancer Epidemiol Biomarkers Prev; 19(10) October 2010 Cancer Epidemiology, Biomarkers & Prevention 2652
consequent bleeding. Conversely, fecal FL-DNA values were significantly higher in patients with sessile rather than with pedunculated lesions and in those with mixed rather than with single lesion localizations, indicating a different relationship between the entire lesion surface and exfoliation of proliferating cells into the colorectal lu-men. These data also suggest that there may be a correla-tion between DNA integrity and/or occult blood levels and some molecular alterations related to adenoma subtypes characterized by exfoliation or bleeding, i.e., proliferation or apoptosis markers. The identification of biological parameters correlated with these markers could enable us to better define the role and importance of the double approach (iFOBT and FL-DNA) for the early diag-nosis of colorectal cancer.
Interesting results were also obtained by evaluating high- and low-risk adenoma subgroups together. In fact, FOBT values were slightly higher in high-risk adeno-mas, whereas FL-DNA values were equally distributed in the two subgroups. It must be pointed out that ade-noma risk classification was based on pathologic para-meters. Conversely, the two markers were probably correlated with other biological characteristics that would be interesting to analyze using a molecular approach.
The novelty of the present study is the sequential use of the diagnostic iFOBT and FL-DNA methods. The double assay showed that, in the subgroups with medium and high iFOBT values, fecal DNA provided more accurate diagnostic information and identified small subgroups with a very different probability of having a tumor.
In conclusion, our results suggest that it could be useful to consider a combined approach based on different markers capable not only of predicting the presence of neoplastic lesions but also of determining a patient's risk
of harboring a preneoplastic or neoplastic lesion. Such information could help clinicians in planning diagnostic tests. However, a number of key issues remain to be clarified to improve the diagnostic accuracy of the tests under investigation, the most important being the fre-quency with which the tests should be carried out, and the number of stool samples that need to be analyzed at specific time points for each individual. It must also be remembered that, although DNA analysis has high sensitivity to detect colorectal cancer, it is, like FOBT, unable to accurately identify all high-risk adenomas, which are important targets for early detection. More-over, our study could not compare the accuracy of either approach as it was limited to patients with iFOBT-positive results, and such data cannot be applied to a screening setting. New methods of increasing diagnostic accuracy for early lesions are thus being evaluated in our laboratory. One such approach is the detection of very small differences in DNA integrity level using real-time PCR. Another is the analysis of epigenetic markers associ-ated with adenoma-cancer transition and with the first phases of tumor transformation.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Acknowledgments
We thank Gráinne Tierney for editing the manuscript.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 03/22/2010; revised 07/08/2010; accepted 07/23/2010; published online 10/07/2010.
References
1. Jemal A, Tiwari RC, Murray T, et al, American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8–29.
2. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004;96:1420–5.
3. Castiglione G, Grazzini G, Ciatto S. Guaiac and immunochemical tests for faecal occult blood in colorectal cancer screening. Br J Cancer 1992;65:942–4.
4. Mandel JS, Bond JH, Church TR, et al, Minnesota Colon Cancer Control Study. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993;328: 1365–71.
5. Robinson MH, Marks CG, Farrands PA, Thomas WM, Hardcastle JD. Population screening for colorectal cancer: comparison between guaiac and immunological faecal occult blood tests. Br J Surg 1994;81:448–51.
6. Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neo-plasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007;99:1462–70.
7. Guittet L, Bouvier V, Mariotte N, et al. Comparison of a guaiac and an immunochemical faecal occult blood test for the detection of colonic lesions according to lesion type and location. Br J Cancer 2009;100: 1230–5.
8. Hundt S, Haug U, Brenner H. Comparative evaluation of
immuno-chemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 2009;150:162–9.
9. Nagasaka T, Tanaka N, Cullings HM, et al. Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J Natl Cancer Inst 2009;101:1244–58.
10. Zou H, Taylor WR, Harrington JJ, et al. High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology 2009;136:459–70.
11. Diehl F, Schmidt K, Durkee KH, et al. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastro-enterology 2008;135:489–98.
12. Osborn NK, Ahlquist DA. Stool screening for colorectal cancer: molecular approaches. Gastroenterology 2005;128:192–206. 13. Lipkin M, Bell B, Sherlock P. Cell proliferation kinetics in the
gastro-intestinal tract of man. I Cell renewal in colon and rectum. J Clin Invest 1963;42:767–76.
14. Ota DM, Drewinko B. Growth kinetics of human colorectal carcino-ma. Cancer Res 1985;45:2128–31.
15. Loktionov A, O'Neill IK, Silvester KR, Cummings JH, Middleton SJ, Miller R. Quantitation of DNA from exfoliated colonocytes isolated from human stool surface as a novel noninvasive screening test for colorectal cancer. Clin Cancer Res 1998;4: 337–42.
screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000;119:1219–27. 17. Boynton KA, Summerhayes IC, Ahlquist DA, Shuber AP. DNA
integrity as a potential marker for stool-based detection of colorectal cancer. Clin Chem 2003;49:1058–65.
18. Calistri D, Rengucci C, Bocchini R, Saragoni L, Zoli W, Amadori D. Fecal multiple molecular tests to detect colorectal cancer in stool. Clin Gastroenterol Hepatol 2003;1:377–83.
19. Calistri D, Rengucci C, Lattuneddu A, et al. Detection of colorectal cancer by a quantitative fluorescence determination of DNA amplifi-cation in stool. Neoplasia 2004;6:536–40.
20. Calistri D, Rengucci C, Molinari C, et al. Quantitative fluorescence determination of long-fragment DNA in stool as a marker for the early detection of colorectal cancer. Cell Oncol 2009;31:11–7.
21. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker
develop-ment for early detection of cancer. J Natl Cancer Inst 2001;93: 1054–61.
22. Gluud C, Gluud LL. Evidence based diagnostics. BMJ 2005;330:724–6. 23. Available from: http://www.nccn.org/professionals/physician_gls/
PDF/colorectal_
screening.pdf), last accessed Jan 2010.
24. Lieberman DA. Clinical practice. Screening for colorectal cancer. N Engl J Med 2009;361:1179–87.
25. Levi Z, Rozen P, Hazazi R, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007;146:244.
26. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME, Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004;351:2704–14.
Calistri et al.
Cancer Epidemiol Biomarkers Prev; 19(10) October 2010 Cancer Epidemiology, Biomarkers & Prevention 2654
